1. Introduction {#sec1-marinedrugs-17-00327}
===============

Seaweeds are an underexploited and sustainable crop which offer a rich source of bioactive compounds, including novel dietary fibres, polyphenols, fatty acids, and carotenoids \[[@B1-marinedrugs-17-00327],[@B2-marinedrugs-17-00327]\]. Epidemiological evidence comparing Japanese and Western diets have correlated seaweed consumption (5.3 g/day in Japan) with decreased incidence of chronic disease \[[@B3-marinedrugs-17-00327]\], while the purported efficacies of seaweed phytochemicals have led to potential functional food and nutraceutical applications which aim to protect against cardiometabolic and inflammatory risk factors associated with non-communicable diseases, such as obesity, type two diabetes, metabolic syndrome, cardiovascular disease, inflammatory bowel disease, and some cancers \[[@B1-marinedrugs-17-00327]\].

Current understanding of mutualistic diet-host-microbe interactions has generated efforts to exploit diet to maintain health status, and to prevent or overcome non-communicable diseases, where an imbalance of gut microbiota composition and metabolic function manifests during the onset and pathophysiology of gastrointestinal, neurological, and cardio-metabolic diseases, often congruent with intestinal inflammation and compromised gut barrier function \[[@B4-marinedrugs-17-00327],[@B5-marinedrugs-17-00327]\]. As such, it has become pertinent to explore dietary strategies which modulate gut microbial composition and function to improve host health. This includes the use of prebiotics as fermentable substrates to enable selective gut commensal metabolism.

The prebiotic definition was recently updated to "a substrate that is selectively utilised by host microorganisms conferring a health benefit" \[[@B6-marinedrugs-17-00327]\], which includes the inhibition of pathogens, immune system activation, and vitamin synthesis and provides opportunity to explore the prebiotic efficacy of non-complex polysaccharide components such polyphenols, phytochemicals, and polyunsaturated fatty acids (PUFAs) \[[@B6-marinedrugs-17-00327]\]. It is also recognised that other microbial species have the potential to catabolise prebiotics, besides the classical examples of *Bifidobacterium* and *Lactobacillus* \[[@B6-marinedrugs-17-00327]\], courtesy of culture-independent techniques, such as 16S rRNA next generation sequencing and whole genome shotgun metagenomic sequencing which have provided taxonomic classification to identify microbial abundance/diversity and inferred or identified metabolic function \[[@B7-marinedrugs-17-00327]\].

Given that previous discussion regarding the prebiotic potential of seaweed components has focused solely upon the saccharolytic fermentation of complex polysaccharides and the physiological effects of short chain fatty acid metabolites (SCFAs) \[[@B3-marinedrugs-17-00327],[@B8-marinedrugs-17-00327],[@B9-marinedrugs-17-00327]\], scope exists to explore the prebiotic potential of other phytochemical components derived from seaweeds, namely polyphenols, carotenoids, and PUFAs, applicable to both human and animal health.

This review aims to provide an updated discussion regarding the fermentation and potential prebiotic effect of seaweed polysaccharides and oligosaccharides, based on recent evidence from in vitro fermentation studies and in vivo animal models, and to postulate how other seaweed phytochemicals, such as polyphenols, PUFAs, and carotenoids, may interact with the gut microbiota to manipulate microbial composition and/or function to elicit bioactivities pertained to a prebiotic. The latter provides new opportunities to complete prebiotic screening studies using in vitro techniques and pre-clinical animal models to understand how parent compound biotransformation into endogenously-derived or gut microbiota-derived metabolites impact bioaccessibility and bioavailability to influence gut microbial community structure and function, conducive to a prebiotic effect. Evidence from clinical trials with health-related end-points and mechanistic insight is imperative to substantiate health claims associated with a prebiotic effect.

2. Complex Polysaccharides {#sec2-marinedrugs-17-00327}
==========================

Seaweeds contain 2.97--71.4% complex polysaccharides \[[@B2-marinedrugs-17-00327],[@B3-marinedrugs-17-00327]\], which include alginate, fucoidan, and laminarin in brown seaweeds; xylan and sulphated galactans, such as agar, carrageenan, and porphyran in red seaweeds; whilst ulvan and xylan are found in green seaweeds. The monosaccharide composition of the major brown, red, and green seaweed glycans are presented in [Table 1](#marinedrugs-17-00327-t001){ref-type="table"}, [Table 2](#marinedrugs-17-00327-t002){ref-type="table"}, [Table 3](#marinedrugs-17-00327-t003){ref-type="table"}, respectively. Whilst no human study to date has explored prebiotic sources from seaweeds, several in vitro studies \[[@B10-marinedrugs-17-00327],[@B11-marinedrugs-17-00327],[@B12-marinedrugs-17-00327],[@B13-marinedrugs-17-00327]\], and in vivo animal studies \[[@B14-marinedrugs-17-00327],[@B15-marinedrugs-17-00327]\], have explored the prebiotic potential seaweeds and their polysaccharide components.

Seaweed polysaccharides are atypical in structure to terrestrial glycans, and are understood to resist gastric acidity, host digestive enzymes, and gastrointestinal absorption \[[@B8-marinedrugs-17-00327]\]. Seaweed glycans may, therefore, serve as fermentation substrates for specific gut microbial populations or facilitate substrate cross-feeding of partially broken-down intermediates, such as oligosaccharides and metabolic cross-feeding of SCFAs to cause indirect proliferation of specific bacteria \[[@B16-marinedrugs-17-00327],[@B17-marinedrugs-17-00327],[@B18-marinedrugs-17-00327],[@B19-marinedrugs-17-00327],[@B20-marinedrugs-17-00327]\]. The physiological effects of SCFAs, primarily acetate, propionate, and butyrate, include the reduction of luminal pH to inhibit pathogens, the provision of energy sources to colonocytes, and the activation of free fatty acid receptors; where acetate and propionate are ligands for anorexigenic pathways in appetite regulation and can inhibit the rate limiting step of hepatic cholesterol synthesis via 3-hydroxy-3-methylglutaryl CoA reductase inhibition \[[@B21-marinedrugs-17-00327],[@B22-marinedrugs-17-00327],[@B23-marinedrugs-17-00327]\].

To facilitate saccharolytic fermentation in the colon, the gut microbiota must express functional carbohydrate active enzymes (CAZymes) to catabolise seaweed glycans as carbon sources within the colonic digesta. The repertoire of CAZymes expressed by the human gut microbiota includes glycoside hydrolase and polysaccharide lyase families to facilitate degradation via hydrolysis and elimination reactions, respectively \[[@B24-marinedrugs-17-00327],[@B25-marinedrugs-17-00327],[@B26-marinedrugs-17-00327]\]. Whole genome sequencing has previously identified gene clusters which encode the catabolic machinery responsible for the breakdown of prebiotics, which includes the CAZyme families responsible for the catabolism of inulin, lactulose, fructo-oligosaccharides, xylo-oligosaccharides, and galacto-oligosaccharides by human gut commensal strains, including *Bifidobacterium longum* NCC2705, *Bifidobacterium adolescentis* ATCC 15703, *Streptococcus thermophilus* LMD9, *Eubacterium rectale* ATCC 33656, *Bacteroides vulgatus* ATCC 8482, and *Fecalibacterium prausnitzii* KLE1255 \[[@B27-marinedrugs-17-00327]\].

Based on open source data from the Carbohydrate-Active enZYmes Database \[[@B28-marinedrugs-17-00327]\], [Table 1](#marinedrugs-17-00327-t001){ref-type="table"}, [Table 2](#marinedrugs-17-00327-t002){ref-type="table"} and [Table 3](#marinedrugs-17-00327-t003){ref-type="table"} detail the CAZyme families which may exert specificity for seaweed glycans and highlights the gut bacterial populations which have demonstrable evidence for seaweed glycan utilisation. This is dominated by *Bacteroides*, which have extensive glycolytic versatility \[[@B26-marinedrugs-17-00327],[@B29-marinedrugs-17-00327]\]. This may explain why in vitro batch culture fermentation data of seaweeds and seaweed glycans indicate the proliferation of *Bacteroides*; whilst the degradation of complex seaweed glycans by *Bacteroides* could also facilitate the cross-feeding of oligosaccharides, monosaccharides, and SCFAs for gut commensals deemed beneficial to health, including *Bifidobacterium*.

In vitro fermentation studies are frequently used as screening tools to model colonic fermentation and determine substrate utilisation by an ex vivo faecal inoculum, with seaweed as a sole carbon source. An overview of recent in vitro fermentation studies which have evaluated the fermentation of whole seaweeds or extracted complex polysaccharide components by the human gut microbiota is presented in [Table 4](#marinedrugs-17-00327-t004){ref-type="table"} (brown seaweeds), [Table 5](#marinedrugs-17-00327-t005){ref-type="table"} (red seaweeds), and [Table 6](#marinedrugs-17-00327-t006){ref-type="table"} (green seaweeds). These tables include differences in study methodologies, for example, test substrate dosage; the use of an in vitro digestion before the fermentation experiment (declared within the methods section of the cited research paper); how the inoculum was prepared; duration of the faecal fermentation experiment; microbial enumeration method; and the analytical technique used to ascertain metabolite changes during the fermentation. The use of an in vitro digestion before in vitro fermentation is often used to determine whether a substrate is resistant to endogenous digestive enzymes and small intestinal absorption, and to provide the fraction of a dietary component which is bioaccessible in the colon \[[@B30-marinedrugs-17-00327]\]. The lack of an in vitro digestion before fermentation experiments may cause false positive results, given that low molecular weight components present in seaweed extracts, normally absorbed in the small intestine, are used as fermentation substrates for the ex vivo microbiota. [Table 7](#marinedrugs-17-00327-t007){ref-type="table"} highlights data from in vivo rodent studies which have evaluated the potential prebiotic effect of seaweeds and seaweed glycans.

2.1. Brown Seaweed Polysaccharides {#sec2dot1-marinedrugs-17-00327}
----------------------------------

Brown seaweeds are commonly used as food ingredients owing to their commercial abundance \[[@B53-marinedrugs-17-00327]\]. The anti-obesogenic effects of brown seaweeds are reported in mice, where supplementation of 5% (*w*/*w*) *Saccorhiza polyschides* extract, containing 12% dietary fibre, reduced body weight gain and fat mass of mice with diet-induced obesity \[[@B54-marinedrugs-17-00327]\]. The anti-obesogenic effect was attributed to the fermentation of alginate and fucoidan complex polysaccharide components, owing to reduced microbial bile salt hydrolase activity; however, no gut microbial compositional data were provided. Elsewhere, the in vitro evidence ([Table 4](#marinedrugs-17-00327-t004){ref-type="table"}) indicates that whole brown seaweeds and their extracted complex polysaccharide components are fermented by the ex vivo faecal microbiota, with increased production of acetate, propionate, butyrate, and total SCFAs reported during fermentation experiments. A corresponding increase in populations, such as *Bifidobacterium, Bacteroides*, *Lactobacillus, Roseburia*, *Parasutterella, Fusicatenibacter*, *Coprococcus, Fecalibacterium* is also reported \[[@B55-marinedrugs-17-00327],[@B56-marinedrugs-17-00327],[@B57-marinedrugs-17-00327]\].

### 2.1.1. Alginate {#sec2dot1dot1-marinedrugs-17-00327}

Alginates are composed of 1,4-linked α-[l]{.smallcaps}-guluronic (G) and β-[d]{.smallcaps}-mannuronic acid (M) residues to form GM, GG and MM blocks, and represent 17−45% dry weight of brown seaweeds \[[@B58-marinedrugs-17-00327]\]. The colloidal properties of alginates have wide application in food processing, biotechnology, medicine and pharmaceutical industries \[[@B59-marinedrugs-17-00327]\], while degraded sodium alginate is an approved item of "foods with specified uses", under the categories of "Foods that act on cholesterol plus gastrointestinal conditions" and "Foods that act on blood cholesterol levels" in Japan \[[@B60-marinedrugs-17-00327]\]. The presence of water soluble alginate oligosaccharides in the faeces of pigs fed alginate is indicative of alginate lyase activity by the luminal or mucus adherent gut microbiota \[[@B61-marinedrugs-17-00327]\], although an adaptation period of \> 39 days is reported for the degradation of G blocks by the porcine microbiota whilst M blocks are readily degraded \[[@B62-marinedrugs-17-00327]\].

The capacity for alginate to modulate the gut microbiota of Japanese individuals was highlighted over 20 years ago \[[@B63-marinedrugs-17-00327]\], where alginate supplementation (30 kDa, 10 g/day, n = 8) significantly increased faecal *Bifidobacterium* populations in healthy male volunteers after both one and two weeks, alongside significantly increased acetic and propionic acids after two weeks. Deleterious metabolites, including faecal sulphide, phenol, p-cresol, indole, ammonia and skatole were significantly reduced compared to the control (free living) diet. Notably, faecal *Bifidobacterium* counts and SCFA concentrations returned to baseline in the week after alginate diet cessation, which highlights the transient nature of the gut microbiota and the need for greater powered long-term human intervention studies.

Subsequent in vitro fermentation studies have indicated that alginate is fermented by the human gut microbiota, for example, a 24 h in vitro fermentation of a 212 kDa alginate increased total bacterial populations, although no statistical increase in individual *Bifidobacterium*, *Bacteroides*/*Prevotella*, *Lactobacillus*/*Enterococcus*, *Eubacterium rectale*/*Clostridium coccoides*, or *Clostridium histolyticum* populations were observed \[[@B11-marinedrugs-17-00327]\]. Acetic acid, propionic acid and total SCFAs were significantly increased after 24 h fermentation with the 212 kDa alginate, while alginate of 97 kDa increased total SCFA and acetate production after 10 h of fermentation. Alginates of 38 kDa, and 97 kDa did not change microbial abundance, although the authors could not correlate molecular weight with fermentation patterns.

Alginate oligosaccharides (AOS) (\~3.5 kDa) can be obtained via acidic or enzymatic hydrolysis of alginate polysaccharides \[[@B58-marinedrugs-17-00327]\], and enzymatically derived AOS has promoted the growth of *Bifidobacterium bifidum* ATCC 29521, *Bifidobacterium longum* SMU 27001 and *Lactobacilli*, in vitro \[[@B64-marinedrugs-17-00327],[@B65-marinedrugs-17-00327]\]. Supplementation of 2.5% AOS for two weeks significantly increased faecal *Bifidobacterium*. in rats compared to control and 5% FOS supplemented diets (13-fold and 4.7-fold increase, respectively), while faecal *Lactobacillus* were 5-fold greater in rats who consumed AOS compared to FOS. *Enterobacteriaceae* and *Enterococcus* populations were significantly decreased following AOS supplementation. Elsewhere, the hydrolysis of alginate, mannuronic acid oligosaccharides (MO) and guluronic oligosaccharides (GO) during a 48 h batch culture fermentation with the faecal microbiota of Chinese individuals demonstrated increased production of acetate, propionate, butyrate, and total SCFAs compared to the substrate-free control, where GO generated the greatest increase \[[@B36-marinedrugs-17-00327]\]. Subsequent strain isolation from the stools of individuals who demonstrated alginate degradation during fermentation identified *Bacteroides xylanisovlens* G25, *Bacteroides thetaiotomicron* A12, *Bacteroides ovatus* A9, and *Bacteroides ovatus* G19 as strains capable of hydrolysing alginate and AOS, where *Bacteroides ovatus* G19 expressed α-1,4-guluronanlyase and β-1,4-mannuronanlyase CAZymes \[[@B34-marinedrugs-17-00327]\].

A *Bacteroides xylanisolvens* strain with 99% similarity to *Bacteroides xylanisolvens* XB1A was recently isolated from the stool of a Chinese individual and the alginate lyase gene expressed was 100% homologous to the alginate lyase of *Bacteroides ovatus* strain ATCC 8483 \[[@B33-marinedrugs-17-00327]\]. The preceding in vitro fermentation study demonstrated increased production of acetate, propionate, butyrate, and total SCFAs compared to the soluble starch control vessel following a 72 h fermentation of alginate.

Alginate lyase depolymerises alginate polysaccharides to lower molecular weight oligosaccharides via β-elimination, and is most commonly expressed by marine bacteria, including *Flammeovirga*, *Vibrio*, *Pseudoalteromonas*, *Glaciecola chathamensis* S18K6, and *Zobellia galactanivorans* \[[@B65-marinedrugs-17-00327],[@B66-marinedrugs-17-00327],[@B67-marinedrugs-17-00327],[@B68-marinedrugs-17-00327],[@B69-marinedrugs-17-00327]\], while the terrestrial bacteria *Paenibacillus* sp. Strain MY03 was recently reported to possess genes encoding alginate lyase and agarase enzymes \[[@B70-marinedrugs-17-00327]\]. The acquisition of genes encoding alginate lyase enzymes by human gut *Bacteroides* is a suggested consequence of horizontal gene transfer from the marine environment \[[@B31-marinedrugs-17-00327],[@B71-marinedrugs-17-00327]\], where seaweed consumption may have provided a vector to exert a selective pressure to induce diet-driven adaptations of the gut microbiota \[[@B35-marinedrugs-17-00327],[@B72-marinedrugs-17-00327],[@B73-marinedrugs-17-00327],[@B74-marinedrugs-17-00327],[@B75-marinedrugs-17-00327],[@B76-marinedrugs-17-00327]\]. Recent work by Matthieu et al. \[[@B35-marinedrugs-17-00327]\] suggests that an alginate degradation system within the genome of human gut *Bacteroides* was a result of ancient acquisition, where the polysaccharide utilisation loci encodes PL6 and PL17 alginate lyase enzymes and hypothetical proteins responsible for alginate recognition, internalisation, and catabolism, including bacterial ABC transporter proteins to facilitate alginate uptake across the bacterial membrane \[[@B77-marinedrugs-17-00327]\]. Nevertheless, in vivo rodent studies have demonstrated that seaweed glycans are fermented even though animals have never been exposed to dietary seaweeds before the intervention, which suggests that the gut microbiome contains genes for CAZymes which can degrade seaweed glycans when expressed.

### 2.1.2. Laminarin {#sec2dot1dot2-marinedrugs-17-00327}

Laminarin is a water-soluble storage polysaccharide consisting of 1,3- or 1,6-β-glucose with an average molecular weight of 5 kDa \[[@B78-marinedrugs-17-00327]\] and accounts for 10--35% of the dry weight of brown seaweeds \[[@B58-marinedrugs-17-00327]\]. One in vitro batch culture fermentation of laminarin demonstrated increased *Bifidobacteria* and *Bacteroides* after 24 h \[[@B79-marinedrugs-17-00327]\], while another demonstrated increased propionate and butyrate production after 24 h \[[@B14-marinedrugs-17-00327]\]. A subsequent in vivo rat study (143 mg laminarin per kg body weight per day for 14 days) indicated that laminarin was not selectively fermented by *Lactobacillus* and *Bifidobacterium*, but could modify jejunal, ileal, caecal and colonic mucus composition, secretion, and metabolism to protect against bacterial translocation. The authors suggest that increased luminal acidity and/or catabolism of laminarin by mucolytic commensals could elicit such effects, which corroborates the evidence that a complex polysaccharide-rich diet maintains mucus layer integrity to promote gut barrier function \[[@B80-marinedrugs-17-00327],[@B81-marinedrugs-17-00327]\]. Future studies regarding intestinal mucus modulation by laminarin may wish to characterise gut microbiota compositional and functional changes following laminarin ingestion, to detect the abundance and metabolic activity of glycan degraders, such as *Bacteroides* \[[@B82-marinedrugs-17-00327],[@B83-marinedrugs-17-00327]\] or mucolytic species associated with health, such as *Akkermansia muciniphila* or *Ruminococcus* \[[@B84-marinedrugs-17-00327],[@B85-marinedrugs-17-00327]\]. Elsewhere, laminarin increased L-cell GLP-1 secretion to attenuate diet-induced obesity in mice, and improved glucose homeostasis and insulin sensitivity \[[@B86-marinedrugs-17-00327]\]. The authors suggested that the observed cytosolic Ca^2+^ cascade caused GLP-1 secretion, which is in agreement with GPR41/43 receptor activation by SCFAs produced by gut microbial fermentation \[[@B87-marinedrugs-17-00327],[@B88-marinedrugs-17-00327]\], however, data obtained to assess laminarin-induced changes to gut microbiota composition and metabolic output is needed to ascribe a prebiotic effect in this study.

The abundance of glycoside hydrolase and β-glucosidase enzymes expressed by the human gut microbiota may have the capacity to catabolise laminarin \[[@B24-marinedrugs-17-00327],[@B89-marinedrugs-17-00327],[@B90-marinedrugs-17-00327],[@B91-marinedrugs-17-00327]\], for example, a *Bacteroides cellulosyliticus* WH2 human gut isolate was able to grow on laminarin-supplemented minimal media in vitro, (incidentally it did not grow on alginate, carrageenan, or porphyran) \[[@B92-marinedrugs-17-00327]\]; however, the molecular mechanisms by which human gut *Bacteroides* breakdown laminarin are likely distinct from those responsible for the degradation of mix linked β 1,3- 1,4- glucans, such as those found in cereals (e.g., by BoGH16~MLG~) \[[@B93-marinedrugs-17-00327]\].

### 2.1.3. Fucoidan {#sec2dot1dot3-marinedrugs-17-00327}

Fucoidans are water soluble polysaccharides composed of sulphated 1,2- or 1,3- or 1,4-α-[l]{.smallcaps}-fucose which exist as structural polysaccharides in brown seaweeds and occupy 5--20% of algal dry weight \[[@B58-marinedrugs-17-00327],[@B94-marinedrugs-17-00327]\]. The structural heterogeneity of fucoidan encompasses varying degrees of branching, sulphate content, polydispersity, and irregular monomer patterns, which can include fucose, uronic acid, galactose, xylose, arabinose, mannose, and glucose residues \[[@B9-marinedrugs-17-00327],[@B59-marinedrugs-17-00327],[@B95-marinedrugs-17-00327]\].

A recent in vitro fermentation study of fucoidan (\<30 kDa) extracted from *Laminaria japonica* demonstrated a greater increase in *Bifidobacterium* and *Lactobacillus* following 24 h and 48 h fermentation relative to \>30 kDa fucoidan \[[@B12-marinedrugs-17-00327]\], while fucoidan from *Ascophyllum nodosum* (1330 kDa) and *Laminaria japonica* (310 kDa) were shown to increase *Lactobacillus* and *Ruminococcaceae*, respectively, in the caecal microbiota of mice gavaged with 100 mg/kg/day \[[@B96-marinedrugs-17-00327]\]. Fucoidan also reduced serum LPS-binding protein levels in this study---indicative of a reduced antigen load and reduced inflammatory response. In contrast, fucoidan with a fucose-rich and highly sulphated fucoidan extracted from *Cladosiphon okamuranus* was not fermented by the rat gut microbiota \[[@B97-marinedrugs-17-00327]\].

While the purported bioactivities of fucoidan include anti-obesogenic, anti-diabetic, anti-microbial, and anti-cancer properties \[[@B98-marinedrugs-17-00327]\], there is limited evidence to implicate a role for the gut microbiota with such bioactivities, and studies are needed to evaluate the structure-dependent fermentation of fucoidan to ascribe a prebiotic effect. For the latter, this is surprising given the myriad of α-fucosidase enzymes present in the human gut bacterial glycobiome.

2.2. Red Seaweed Polysaccharides {#sec2dot2-marinedrugs-17-00327}
--------------------------------

### 2.2.1. Galactans (Carrageenan, Agar, and Porphyran) {#sec2dot2dot1-marinedrugs-17-00327}

Red seaweeds, such as *Gelidium* spp. and *Gracilaria* spp., are used in the commercial production of agar and carrageenan food additives, including thickening, stabilizing and encapsulation agents \[[@B53-marinedrugs-17-00327]\]. A summary of evidence from recent in vitro fermentation experiments using red seaweed-derived substrates are presented in [Table 5](#marinedrugs-17-00327-t005){ref-type="table"}.

Carrageenans are composed of sulphated 1,4-β-[d]{.smallcaps}-galactose, 1,3-α-[d]{.smallcaps}-galactose, and 3,6-anhydro-[d]{.smallcaps}-galactose \[[@B43-marinedrugs-17-00327]\], and constitutes 30−75% dry weight of red seaweeds \[[@B58-marinedrugs-17-00327]\]. In rats fed 2.5% *Chondrus crispus*, of which carrageenan is a major polysaccharide component, faecal *Bifidobacterium breve*, and acetate, propionate, and butyrate SCFAs were significantly increased alongside a significant decrease in the pathogens *Clostridium septicum* and *Streptococcus pneumonia*, as compared to the basal diet \[[@B15-marinedrugs-17-00327]\]. Furthermore, a 1:1 mixture of polysaccharide extracts from *Kappaphycus alvarezii* (containing carrageenan) and *Sargassum polycystum* (brown seaweed) has lowered serum lipids in rats \[[@B39-marinedrugs-17-00327]\]. In a study by Li et al. \[[@B34-marinedrugs-17-00327]\], β-carrageenase activity in a *Bacteroides uniforms* 38F6 isolate complex of *Bacteroides xylanisolvens* and *Escherichia coli* hydrolysed κ-carrageenan oligosaccharides into 4-*O*-sulfate-[d]{.smallcaps}-galactose, κ-carratriose, κ-carrapentaose, and κ-carraheptaose, which could facilitate cross-feeding to promote the growth of *Bifidobacterium* populations.

Agar is composed of sulphated 1,3-β-[d]{.smallcaps}-galactose and 1,4- 3,6-anhydro-α-[l]{.smallcaps}-galactose \[[@B40-marinedrugs-17-00327]\] and can be fractionated into agarose and agaropectin \[[@B8-marinedrugs-17-00327]\]. Low molecular weight agar of 64.64 kDa has demonstrated a bifidogenic effect alongside increased acetate and propionate SCFA concentrations after 24 h in vitro fermentation with human stool inoculum \[[@B11-marinedrugs-17-00327]\], while mice fed with 2.5% (*w*/*v*) neoagarose oligosaccharides for 7 days demonstrated increased caecal and faecal *Lactobacillus* and *Bifidobacterium* \[[@B102-marinedrugs-17-00327]\]. The utilisation of agaro-oligosaccharides was noted in vitro by *Bacteroides uniforms* L8, isolated from Chinese individuals, which secreted a β-agarase CAZyme to breakdown agarooligosaccharides into agarotriose and subsequently facilitated the growth of *Bifidobacterium infantis* and *Bifidobacterium adolescentis* via the cross feeding of agarotriose \[[@B103-marinedrugs-17-00327]\].

Porphyran is made up of sulphated 1,3-β-[d]{.smallcaps}-galactose, 1,4-α-[l]{.smallcaps}-galactose-6-sulfate and 3,6-anhydro-α-[l]{.smallcaps}-galactose \[[@B41-marinedrugs-17-00327],[@B104-marinedrugs-17-00327],[@B105-marinedrugs-17-00327]\]. An in vitro faecal fermentation study indicated that porphyran did not significantly increase SCFAs, but stimulated *Lactobacillus* and *Bacteroides* populations \[[@B79-marinedrugs-17-00327]\]. While pure cultures of *Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium adolescentis,* but not *Bifidobacterium bifidum*, were able to ferment dried *Porphyra yezoensis* (Nori), containing a low protein content (25%), whereas Nori with a high protein content (41%) was not fermented \[[@B105-marinedrugs-17-00327]\]. It is likely that carbohydrate content was highest in the low protein Nori, thus seasonal- and species-variation and in seaweed macronutrient content should be considered a determinant factor for the fermentability of whole seaweeds \[[@B106-marinedrugs-17-00327],[@B107-marinedrugs-17-00327],[@B108-marinedrugs-17-00327],[@B109-marinedrugs-17-00327]\].

Evidence for the horizontal transfer of genes for porphyranase and agarase CAZymes from the marine bacteria, *Zobellia galactanivorans*, to *Bacteroides plebeius* of Japanese individuals is indicative of diet-driven adaptations of the human gut microbiome \[[@B41-marinedrugs-17-00327],[@B44-marinedrugs-17-00327]\]; however, the North American counterparts in this study did not consume seaweeds and the gut microbiota of these individuals did not express such CAZymes. This may mean that the fermentation of seaweed polysaccharides, such as porphyran and agar, requires exposure to, and acquisition of, specific CAZymes usually present in the marine environment \[[@B73-marinedrugs-17-00327]\]. Red seaweed galactans are emerging prebiotic candidates given the commercial availability of red seaweed hydrocolloids and the potential gut modulatory effects of oligosaccharides obtained from red seaweeds. Nevertheless, further in vivo evidence is needed, given the purported pro-inflammatory effects of low molecular weight carrageenan \[[@B110-marinedrugs-17-00327],[@B111-marinedrugs-17-00327],[@B112-marinedrugs-17-00327]\].

### 2.2.2. Xylan {#sec2dot2dot2-marinedrugs-17-00327}

Xylan, composed of 1,3-1,4-β-D-xylose, is a major constituent of red seaweeds, such as *Palmaria palmata* \[[@B46-marinedrugs-17-00327]\]. A previous in vitro faecal fermentation study of xylan derived from *P*. *palmata*, reported that xylose was fermented after six h alongside a 58:28:14 ratio of acetate, propionate, and butyrate SCFAs (total SCFAs were 107 mM/L) \[[@B113-marinedrugs-17-00327]\]. This study did not ascertain bacterial compositional data, and thus a knowledge gap is presented given that xylans and xylooligosaccharides (XOS) extracted from terrestrial plants, such as wheat husks and maize, are mooted as potential prebiotics owing to evidence of bifidogenesis, improved plasma lipid profile, and positive modulation of immune function markers in healthy adults \[[@B114-marinedrugs-17-00327],[@B115-marinedrugs-17-00327]\]. Given that human gut *Bacteroides* express a repertoire of xylanase and xylosidase CAZymes \[[@B116-marinedrugs-17-00327]\], investigations regarding the capacity of the human gut microbiota to catabolise red seaweed xylans and XOS are suggested.

2.3. Green Seaweed Polysaccharides {#sec2dot3-marinedrugs-17-00327}
----------------------------------

### Ulvan

Ulvans are water-soluble cell wall polysaccharides that account for 8--29% dry weight of green seaweeds, and are composed of sulphated 1,3-α-[l]{.smallcaps}-rhamnose, 1,4-β-[d]{.smallcaps}-glucuronic acid, and 1,4-β-[d]{.smallcaps}-xyloglucan \[[@B51-marinedrugs-17-00327]\]. Previous reports indicate that *Ulva lactuca* and ulvan polysaccharides are poorly fermented by the human gut microbiota \[[@B8-marinedrugs-17-00327],[@B95-marinedrugs-17-00327],[@B118-marinedrugs-17-00327]\], while an in vitro fermentation study of *Enteromorpha* spp. With a human faecal inoculum reported no difference in *Enterococcus, Lactobacillus*, and *Bifidobacterium* populations compared to the control; only an increase in *Enterobacter* after 24 h and 48 h of fermentation ([Table 6](#marinedrugs-17-00327-t006){ref-type="table"}) \[[@B12-marinedrugs-17-00327]\]. In contrast, a recent in vitro faecal fermentation study indicated that Ulvan stimulated the growth of *Bifidobacterium* and *Lactobacillus* populations and promoted the production of lactate and acetate \[[@B79-marinedrugs-17-00327]\]. Further, a murine study showed that *Enteromorpha* (EP) and *Enteromorpha* polysaccharides (PEP) ameliorated inflammation associated with Loperamide-induced constipation in mice \[[@B119-marinedrugs-17-00327]\], where alpha diversity, Firmicutes, and Actinobacteria were increased in the faecal microbiota of seaweed-supplemented mice compared to the constipated control. Bacteroidetes and Proteobacteria were decreased, while Bacteroidales family *S24-7* and *Prevotellaceae* were increased in EP and PEP, respectively. Current evidence for the fermentation of green seaweeds and their polysaccharides is limited and fermentation may require specific α-[l]{.smallcaps}-rhamnosidase activity by gut commensals \[[@B50-marinedrugs-17-00327]\]. More experimental evidence is needed to understand the impact of ulvans and ulvan-oligosaccharides in the human and animal diet.

2.4. Future Prospective--Obtaining Oligosaccharides {#sec2dot4-marinedrugs-17-00327}
---------------------------------------------------

Enzyme technologies are reported to increase the extraction yield and reduce the molecular weight of bioactive components obtained from seaweeds, with examples of enhanced prebiotic activity when commercially available cellulases or seaweed-specific enzymes were used to hydrolyse polysaccharides \[[@B99-marinedrugs-17-00327],[@B120-marinedrugs-17-00327]\]. Despite limited commercial availability of seaweed-specific enzymes, an avenue for functional oligosaccharide production is presented if efforts to develop commercially viable saccharolytic enzymes from microorganisms (primarily marine). Examples of such glycoside hydrolases include fucoidanase from *Sphingomonas paucimobilis* PF-1 \[[@B121-marinedrugs-17-00327]\]; ulvan lyase from *Alteromonas* spp. \[[@B122-marinedrugs-17-00327]\] and the family *Flavobacteriaceae* \[[@B123-marinedrugs-17-00327]\]; β-agarase from *Cellulophaga omnivescoria* W5C \[[@B124-marinedrugs-17-00327]\] and *Cellvibrio PR1* \[[@B125-marinedrugs-17-00327]\]; alginate lyase from *Flammeovirga* \[[@B126-marinedrugs-17-00327]\], and *Paenibacillus* \[[@B70-marinedrugs-17-00327]\]; and laminarinase from *Clostridiium thermocellum* \[[@B127-marinedrugs-17-00327]\]. Factors which influence the stability and efficacy of such hydrolytic enzymes may include metal ion interaction, or thermostability at the high temperatures needed to prevent gelling of polysaccharides. Recent insight into the production of agarose oligosaccharides and neoagarose oligosaccharides from agar exemplify this \[[@B128-marinedrugs-17-00327]\].

3. Polyphenols {#sec3-marinedrugs-17-00327}
==============

Seaweeds are rich in polyphenols, such as catechins, flavonols, and phlorotannins. Red and green seaweeds are a source of bromophenols, phenolic acids, and flavonoids \[[@B132-marinedrugs-17-00327]\], while phlorotannins are the most abundant polyphenol in brown seaweeds. Most research to date concerns the bioactivity of phlorotannins, a class of polyphenol unique to brown algae comprised of phloroglucinol monomers and categorised as eckols, fucols, fuhalols, ishofuhalols, phloroethols, or fucophloroethols \[[@B132-marinedrugs-17-00327]\]. The purported bioactivities of seaweed polyphenols are associated with the mitigation of risk factors pertained to type 2 diabetes and cardiovascular disease, including hyperglycemia, hyperlipidemia, inflammation and oxidative stress \[[@B133-marinedrugs-17-00327],[@B134-marinedrugs-17-00327],[@B135-marinedrugs-17-00327],[@B136-marinedrugs-17-00327],[@B137-marinedrugs-17-00327]\], and also anti-microbial activity \[[@B138-marinedrugs-17-00327]\]. Owing to heterogeneity in both molecular weight and the level of isomerisation, characterisation of polyphenols is difficult \[[@B139-marinedrugs-17-00327],[@B140-marinedrugs-17-00327],[@B141-marinedrugs-17-00327]\], and a paucity of information exists regarding the endogenous digestion and microbial catabolism of seaweed polyphenols, with a scarce mechanistic understanding of how they may exert health benefits via the gut microbiota.

Most polyphenols of plant origin must undergo intestinal biotransformation by endogenous enzymes and the gut microbiota prior to absorption across enterocytes. These enzymatic transformations include the elimination of glycosidic bonds, for example, flavonoids are converted to glycones (sugars) and aglycones (non-sugars--polyphenols) by endogenous β-glucosidases in the small intestine \[[@B142-marinedrugs-17-00327]\]. The transport of aglycones to the liver via the portal vein results in phase II biotransformation (coupling reactions, chiefly hepatic conjugation to O-glucuronides and O-sulfates) to facilitate urinary and biliary elimination. Phase II metabolites are absorbed into the systemic circulation, or excreted in bile and re-enter the duodenum (hepatic recycling), where subsequent glucuronidase, glycosidase, or sulphatase-mediated deconjugation by the colonic microbiota may favour aglycone reabsorption \[[@B143-marinedrugs-17-00327]\].

Approximately 90--95% of dietary polyphenols reach the colon intact \[[@B144-marinedrugs-17-00327]\], where biotransformation and metabolism by the gut microbiota occurs via hydrolysis, reduction, decarboxylation, demethylation, dehydroxylation, isomerisation, and fission \[[@B145-marinedrugs-17-00327]\], to produce low-molecular weight compounds with less chemical heterogeneity than the polyphenol parent compound \[[@B142-marinedrugs-17-00327]\]. It is suggested that a complex network of gut microbial species is necessary for full biotransformation of polyphenols, whereas simple reactions, such as deglycosylation, can be achieved by individual gut strains. Furthermore, the bioactivities associated with dietary polyphenol intake may be dependent on the catabolic capacity and composition of the gut microbiota, owing to the biological activity of metabolites rather than the parent polyphenol compound present in food \[[@B146-marinedrugs-17-00327],[@B147-marinedrugs-17-00327]\], while a synergistic effect between prebiotic polyphenols and probiotic bacteria may occur \[[@B6-marinedrugs-17-00327]\].

The identification of bacteria which possess the metabolic capabilities to utilise polyphenols was previously identified in *Eubacterium oxidoreducens*, which could catabolise gallate, pyrogallol, phloroglucinol and quercetin \[[@B148-marinedrugs-17-00327]\]. Quercetin biotransformation by *Eubacterium ramulus* has also been identified \[[@B149-marinedrugs-17-00327]\], and multiple human gut microbes which possess phenolic enzymes capable of breaking down glycosides, glucuronides, sulphates, esters, and lactones was summarised by Selma et al. \[[@B145-marinedrugs-17-00327]\]. Such microorganisms included *E. coli* with β-glucuronidase activity; *Eubacterium*, *Bacteroides*, and *Clostridium* with β-glucosidase activity; *Lactobacillus*, *Eubacterium*, *Clostridium* , *Butyrbacterium*, *Streptococcus*, and *Methylotrophicum* with demethylase activity; and *E. coli*, *Bifidobacterium*, *Lactobacillus*, *Bacteroides*, *Streptococcus* , *Ruminococcus*, and *Enterococcus* with esterase activity. There is also evidence for α-[l]{.smallcaps}-Rhamnosidase mediated hydrolysis of rutinose, present on glycosylated polyphenols (rhamnoglycosides), to produce aglycones, by species, such as *Bacteroides thetaiotaomicron* \[[@B50-marinedrugs-17-00327]\], *Bifidobacterium dentium* \[[@B150-marinedrugs-17-00327]\], *Bifidobacterium catenulatum* \[[@B151-marinedrugs-17-00327]\], *Bifidobacterium pseudocatenulatum* \[[@B151-marinedrugs-17-00327]\], and *Lactobacillus plantarum* \[[@B152-marinedrugs-17-00327]\].

Current knowledge regarding the fate of seaweed polyphenols in the human gastrointestinal tract is scarce; however, it is understood that the limited absorption of *Ascophyllum nodosum* polyphenols from small intestinal enterocytes to the portal vein may facilitate the conjugation of polyphenols to methylated, glucuronidated, or sulphated forms rather than hydrolysis to aglycones \[[@B153-marinedrugs-17-00327],[@B154-marinedrugs-17-00327]\]. Subsequently, unabsorbed conjugated polyphenols are available for biotransformation by the colonic microbiota, then potentially absorbed across the colonocytes. Indeed, Corona et al. \[[@B154-marinedrugs-17-00327]\], observed a reduction of total polyphenol contents of an *Ascophyllum nodosum* polyphenol extract, high molecular weight fraction (\>10 kDa), and low molecular weight fraction (1--10 kDa) following in vitro digestion and batch culture fermentation; although anti-genotoxic activity against H~2~O~2~ induced DNA damage of HT-29 cells was increased (to a greater extent by the high molecular weight fraction). This study did not assess the microbiota composition, however, elsewhere, an in vitro fermentation of an *Ecklonia radiata* phlorotannin extract significantly increased *Bacteroidetes*, *Clostridium coccoides*, *E. coli*, and *Fecalibacterium prausnitzii*, but decreased *Bifidobacterium* and *Lactobacillus* populations after 24 h fermentation \[[@B56-marinedrugs-17-00327]\]. More in vitro digestion studies would be useful to understand the stability of seaweed polyphenols as extracts or within the seaweed matrix \[[@B155-marinedrugs-17-00327],[@B156-marinedrugs-17-00327]\]. These studies may be complemented by studies which use ileostomy patient cohorts to determine structural changes to seaweed polyphenols following upper GI digestion in vivo to indicate polyphenol bioaccessibility in the colon \[[@B157-marinedrugs-17-00327]\].

A recent review highlighted the potential for dietary polyphenols to modulate the gut microbiota by increasing *Bifidobacterium, Lactobacillus, Bacteroides*, *Enterococcus, Akkermansia muciniphila*, and *Fecalibacterium prausnitzii* populations \[[@B158-marinedrugs-17-00327]\]. This review did not include any studies which assessed modulation of the gut microbiota by seaweed polyphenols and, therefore, a research opportunity is presented. Inter-individual variation of gut microbiota composition and function is the key determinant for gut microbiota-mediated biotransformation of phenolic compounds to bioactive metabolites \[[@B159-marinedrugs-17-00327],[@B160-marinedrugs-17-00327]\]. Therefore, identification of bacterial species or strains with the ability to catabolise seaweed polyphenols and their respective catabolic machinery is needed to understand if seaweed polyphenols could be prebiotic \[[@B161-marinedrugs-17-00327],[@B162-marinedrugs-17-00327]\]. Moreover, considering that gut microbiota-derived secondary metabolites reach a peak plasma concentration much later than the original aglycone or hepatic conjugates, controlled nutrikinetic studies could elude how dietary polyphenols from seaweeds interact with host-microbiota metabolism \[[@B163-marinedrugs-17-00327],[@B164-marinedrugs-17-00327]\]. Identification of faecal, urinary, serum, or tissue biomarkers via untargeted and targeted metabolomics approaches, and the use of stable isotope studies, may also indicate variation in synthesis, bioavailability, metabolism, and excretion of polyphenols and associated metabolites. While integration of dose response studies alongside metagenomics and metabolomics analyses, akin to those conducted for berry and wine polyphenols, could elude how much seaweed polyphenol is required to have an impact, if any, on gut microbial composition, metabolic function, and host health \[[@B165-marinedrugs-17-00327],[@B166-marinedrugs-17-00327]\].

4. Other Seaweed Phytochemicals {#sec4-marinedrugs-17-00327}
===============================

4.1. Carotenoids {#sec4dot1-marinedrugs-17-00327}
----------------

Carotenoids are lipid soluble compounds which function within the photosynthetic machinery of seaweeds to produce pigments. Fucoxanthin is the predominant carotenoid in brown seaweeds \[[@B167-marinedrugs-17-00327]\], while lutein, β-carotene, astaxanthin, echinenone, violaxanthin, neoxanthin, and zeaxanthin are found in red and green seaweeds. Carotenoids are used as food colouring additives, while the application of fucoxanthin as functional food ingredients is suggested, owing to putative anti-oxidant, anti-inflammatory, anti-cancer, anti-obesity, and anti-diabetic bioactivities \[[@B168-marinedrugs-17-00327],[@B169-marinedrugs-17-00327],[@B170-marinedrugs-17-00327],[@B171-marinedrugs-17-00327],[@B172-marinedrugs-17-00327],[@B173-marinedrugs-17-00327]\].

While some carotenoids are absorbed by enterocytes and converted into vitamin A and retinoid derivatives by endogenous beta-carotene oxygenase 1 (BCO1) and beta-carotene dioxygenase 2 (BCO2) enzymes \[[@B174-marinedrugs-17-00327],[@B175-marinedrugs-17-00327]\], the bioavailability of carotenoids in the blood is reported as 10−40% \[[@B176-marinedrugs-17-00327]\], which has led to suggestions that carotenoids could be fermented by the gut microbiota \[[@B174-marinedrugs-17-00327],[@B177-marinedrugs-17-00327]\]. The only evidence to date has demonstrated that male C57BL/6J mice supplemented with 0.04% (*w*/*w*) astaxanthin during an eight-week pilot study had increased abundance of caecal *Bifidobacterium* \[[@B178-marinedrugs-17-00327]\], whereas *Proteobacteria* and *Bacteroides* were significantly increased in the caecum of BCO2 knockout mice; however, analysis of health biomarkers was not reported. Given the differences in microbiota composition between wild type and BCO2 knockout mice in this study, there is scope to investigate how carotenoids and their endogenous derivatives interact with the gut microbiota. Looking ahead, the use of in vitro models of gastrointestinal digestion and colonic fermentation would be useful to assess whether there is a direct substrate to microbiota effect or a host--microbe effect \[[@B179-marinedrugs-17-00327]\].

4.2. Polyunsaturated Fatty Acids (PUFAs) {#sec4dot2-marinedrugs-17-00327}
----------------------------------------

The lipid content of seaweed ranges from 1--5% dry weight, which includes n-3 PUFAs, such as eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA) \[[@B180-marinedrugs-17-00327],[@B181-marinedrugs-17-00327]\]. The n-3 PUFA are associated with the anti-inflammatory activity to reduce cardiovascular disease risk and may also exert beneficial effects on brain function and behaviour, as mediated by the microbiota-gut-brain axis \[[@B182-marinedrugs-17-00327]\]. Dietary EPA and DHA intake are reported to improve microbial diversity, reduce the Firmicutes/Bacteroidetes ratio, reduce LPS-producing bacteria, and increase populations of *Bifidobacterium*, *Lachnospiraceae*, and lipopolysaccharide (LPS)-suppressing bacteria in both humans and animal models \[[@B182-marinedrugs-17-00327],[@B183-marinedrugs-17-00327],[@B184-marinedrugs-17-00327]\]. Although the evidence to date has focused on fish-derived n-3 PUFA, great scope exists to evaluate the prebiotic effect of n-3 PUFA obtained from seaweeds.

5. Fermented Foods {#sec5-marinedrugs-17-00327}
==================

Fermented foods are understood to have improved nutritional and functional properties owing to bioactive or bioavailable components \[[@B185-marinedrugs-17-00327]\]. Seaweeds (mainly kelp) are a common vegetable ingredient in the fermented food, Kimchi. The microbial content of kimchi provides a source of probiotics, nutrients, and bioactive metabolites, which are reported to have anti-microbial, anti-oxidant, and anti-obesogenic activities \[[@B186-marinedrugs-17-00327],[@B187-marinedrugs-17-00327],[@B188-marinedrugs-17-00327]\]. One randomised controlled trial (RCT) observed that consumption of a seaweed Kimchi made from *L. japonica* for four weeks promoted the growth and survival of gut microbial lactic acid bacteria in humans \[[@B189-marinedrugs-17-00327]\], whilst another RCT concluded that consumption of 1.5 g/day fermented *L. japonica* containing 5.56% γ-aminobutyric acid (GABA) (*Lactobacillus brevis* BJ2 culture) was associated with a reduction in oxidative stress in healthy adults over four weeks, indicated by decreased serum γ-glutamyltransferse (GGT) and malondialdehyde, and increased antioxidant activity of superoxide dismutase and catalase compared to the placebo \[[@B190-marinedrugs-17-00327]\]. The latter study indicates that foods containing fermented brown seaweeds, such as *L. japonica*, may offer a novel source of GABA enriched ingredients, which are associated with hypotensive and anti-inflammatory effects \[[@B188-marinedrugs-17-00327]\]. Anti-oxidant, anti-diabetic, and anti-hypertensive efficacies are also reported for Korean rice wine fermented with *L. japonica* \[[@B191-marinedrugs-17-00327]\], while *Sargassum* fermented with a starter culture of *Enterococcus faecium* was reported to contain higher soluble polyphenol and mannuronic acid-rich alginate contents \[[@B192-marinedrugs-17-00327]\], which may increase the provision of microbiota accessible components for colonic fermentation.

Reports of the functional properties of fermented foods containing red seaweeds are scarce; however, examples of red seaweed fermented foods include a fermented *Porphyra yezoensis* seaweed sauce, which used the marine halophilic lactic acid bacteria, *Tetragenococcus halophilus*, as a starter culture \[[@B193-marinedrugs-17-00327]\]; a *Gracilaria domingensis* aqueous extract applied as a texture modifier in fermented milks as a non-animal alternative to gelatin \[[@B194-marinedrugs-17-00327]\]; and carrageenan as a salt replacer in the production of fat-free cheese \[[@B195-marinedrugs-17-00327]\].

Given the availability of red, brown, and green seaweeds both commercially and locally \[[@B196-marinedrugs-17-00327]\], the production of seaweed-containing fermented foods could be a cost-effective alternative to bioactive component extraction. Nevertheless, an understanding of how live bacteria and bacterial metabolites present in fermented foods contribute towards health is required \[[@B185-marinedrugs-17-00327]\].

6. Seaweeds and Animal Health {#sec6-marinedrugs-17-00327}
=============================

Seaweeds also have a historical use as animal feed ingredients \[[@B197-marinedrugs-17-00327]\]. The capacity for seaweeds to modulate the gut microbiota of monogastrics, such as pigs and hens, is presented in [Table 8](#marinedrugs-17-00327-t008){ref-type="table"} and [Table 9](#marinedrugs-17-00327-t009){ref-type="table"}, respectively, which complements the recent evidence for the application of seaweed bioactives in monogastric animal feed \[[@B198-marinedrugs-17-00327]\]. [Table 8](#marinedrugs-17-00327-t008){ref-type="table"} shows limited evidence that the β-glucan, laminarin, may increase *Lactobacillus* populations but not *Bifidobacterium* populations. While there is scarce evidence for the selective stimulation of health-associated bacteria in pigs by the sulphated fucose, fucoidan. Only one recent study has evaluated the effect of dietary alginate on the porcine microbiota, where the genera *Ruminococcus*, *Roseburia* and *Lachnospira*, and an unclassified bacterium of the *F16* family were increased, alongside a significant decrease in the genus *Blautia,* the family *Clostridiaceae*, and an unclassified bacterium of *RF39* family \[[@B199-marinedrugs-17-00327]\]. In [Table 9](#marinedrugs-17-00327-t009){ref-type="table"}, recent evidence indicates that hens fed *Chondrus crispus* and *Sarcodiotheca gaudichaudii* red seaweeds may increase ceacal SCFA concentrations and modulate populations of *Bifidobacterium longum*, *Lactobacillus acidophilus*, *Streptococcus salivarius*, and *Clostridium perfringens* \[[@B200-marinedrugs-17-00327],[@B201-marinedrugs-17-00327]\]; however, a bidirectional change in microbial composition was dose dependent and has only been assessed in two studies to date. Given the use of pigs as an animal model of humans \[[@B202-marinedrugs-17-00327]\], data from in vivo monogastric studies which are designed to evaluate the prebiotic potential of dietary seaweeds and seaweed-derived components could provide insight into the potential for human applications.

[Table 10](#marinedrugs-17-00327-t010){ref-type="table"} and [Table 11](#marinedrugs-17-00327-t011){ref-type="table"} summarise recent studies which have examined the impact of seaweed diets on the ruminant microbiota of cows and sheep, respectively, with the potential application of reducing methane production. Despite demonstrating decreased methane production, the cow rumen in vitro fermentation studies presented in [Table 10](#marinedrugs-17-00327-t010){ref-type="table"} did not assess microbiota compositional changes, thus a knowledge gap is presented to understand which bacteria (if any), are increased or decreased, and are associated with a reduction in methane production. [Table 11](#marinedrugs-17-00327-t011){ref-type="table"} shows that methanogenic bacteria and methane production were significantly decreased compared to the basal grass substrate control following the in vitro fermentation of sheep rumen with the red seaweed *Asparagopsis taxiformis* \[[@B203-marinedrugs-17-00327]\]. While sheep given an ad libitum diet of *Ascophyllum nodosum* brown seaweed (1%, 3%, or 5% *w*/*w*) for 21 days demonstrated a dose-dependent decrease in propionate and butyrate SCFAs and a dose-dependent increase in acetate \[[@B204-marinedrugs-17-00327]\], while several bacteria were significantly decreased, including *Prevotella copri*, *Roseburia,* and *Coprococcus*, while *Blautia producta* and the family *Veillonellaceae* were significantly increased compared to the basal diet. Moreover, the specific case of seaweed-fed North Ronaldsay sheep highlights how isolated organisms of the ruminant microbiome, such as *Prevotella*, *Clostridium butyricum*, *Butyrivibrio fibrisolvens*, and Spirochaetes have adapted to hydrolyse alginate laminarin, and fucoidan \[[@B205-marinedrugs-17-00327],[@B206-marinedrugs-17-00327]\]. However, there is a paucity of evidence to implicate any health benefits attributed to a seaweed diet in these animals.

7. Conclusions {#sec7-marinedrugs-17-00327}
==============

Current evidence regarding the prebiotic effects of seaweeds is dominated by complex polysaccharide components. This is because prebiotic research was previously focused on saccharolytic fermentation by the gut microbiota. Accumulating evidence from in vitro and in vivo animal studies provides encouraging data regarding the utilisation of red seaweed galactans and brown seaweed glycans, such as alginates and laminarins, with minor evidence for fucoidan and the green seaweed polysaccharide, ulvan.

Given that the most recent definition of prebiotic places non-complex polysaccharide components in vogue, an opportunity is presented to explore how other seaweed phytochemicals, including polyphenols, carotenoids, and PUFAs, are metabolised by host microbial populations to benefit host health. Future investigations should consider the use of in vitro screening studies and in vivo animal studies to identify putative prebiotic compounds from seaweeds via the identification of host organisms which utilise seaweed components and the bioactive metabolites produced (via untargeted metabolomics). Furthermore, controlled human intervention studies with health-related end points to elucidate prebiotic efficacy are required.
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marinedrugs-17-00327-t001_Table 1

###### 

Potential degradation of brown seaweed glycans by the human gut microbiota.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Carbohydrate                            Carbohydrate-Active Enzyme (CAZyme)              Evidenced Glycolytic Bacteria                                                                                                                                                 Reference                        
  --------------------------------------- ------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- -------------------------------------------------------------
  Alginate                                1,4-β-[d]{.smallcaps}-mannuronic acid\           PL6 Alginate lyase\                                                                                                                                                           *Bacteroides clarus*\            
                                          α-[l]{.smallcaps}-guluronic acid                 PL6 MG-specific alginate lyase                                                                                                                                                *Bacteroides eggerthii*          

  PL15 Alginate lyase\                    *Bacteroides ovatus*\                            \[[@B31-marinedrugs-17-00327],[@B32-marinedrugs-17-00327],[@B33-marinedrugs-17-00327],[@B34-marinedrugs-17-00327],[@B35-marinedrugs-17-00327],[@B36-marinedrugs-17-00327]\]                                    
  PL15 Oligoalginate lyase                *Bacteroides thetaiotaomicron*\                                                                                                                                                                                                                                 
                                          *Bacteroides xylanisolvens*                                                                                                                                                                                                                                     

  PL17 Alginate lyase\                    *Bacteroides clarus*\                                                                                                                                                                                                                                           
  PL17 Oligoalginate lyase                *Bacteroides eggerthii*                                                                                                                                                                                                                                         

  Fucoidan                                Sulphated 1,2-1,3-1,4-α-[l]{.smallcaps}-fucose   GH29 α-[l]{.smallcaps}-fucosidase\                                                                                                                                            Not determined                   \[[@B37-marinedrugs-17-00327]\]
                                                                                           GH29 α-1,3/1,4-[l]{.smallcaps}-fucosidase                                                                                                                                                                      

  GH95 α-[l]{.smallcaps}-fucosidase\                                                                                                                                                                                                                                                                      
  GH95 α-1,2-[l]{.smallcaps}-fucosidase                                                                                                                                                                                                                                                                   

  Laminarin                               1,3-1,6-β-glucose                                GH16 β-glucanase\                                                                                                                                                             *Bacteroides distasonis*\        \[[@B10-marinedrugs-17-00327],[@B38-marinedrugs-17-00327]\]
                                                                                           GH16 β-1,3-1,4-glucanase\                                                                                                                                                     *Bacteroides fragilis*\          
                                                                                           GH16 endo-1,3-β-glucanase                                                                                                                                                     *Bacteroides thetaiotaomicron*   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PL, Polysaccharide Lyase family; GH, Glycoside Hydrolase family. Potential glycolytic bacteria were identified using the Carbohydrate-Active enZYmes Database \[[@B28-marinedrugs-17-00327]\].

marinedrugs-17-00327-t002_Table 2

###### 

Potential degradation of red seaweed glycans by the human gut microbiota.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Carbohydrate                                            Carbohydrate-Active Enzyme (CAZyme)           Evidenced Glycolytic Bacteria   Reference                  
  ------------------------------------------------------- --------------------------------------------- ------------------------------- -------------------------- ---------------------------------------------------------------------------------------------------------------------
  Agar (Galactan)                                         1,3-β-[d]{.smallcaps}-galactose\              GH2 β-galactosidase             *Bacteroidetes plebeius*   \[[@B39-marinedrugs-17-00327],[@B40-marinedrugs-17-00327],[@B41-marinedrugs-17-00327],[@B42-marinedrugs-17-00327]\]
                                                          1,4-3,6-anhydro-α-[l]{.smallcaps}-galactose                                                              

  GH16 β-agarase                                                                                                                                                   

  GH86 β-agarase                                                                                                                                                   

  GH117 1,3-α-3,6-anhydro-[l]{.smallcaps}-galactosidase                                                                                                            

  Carrageenan (Galactan)                                  1,4-β-[d]{.smallcaps}-galactose\              GH2 β-galactosidase             *Bacteroides plebeius*     \[[@B41-marinedrugs-17-00327],[@B43-marinedrugs-17-00327]\]
                                                          1,3-α-[d]{.smallcaps}-galactose\                                                                         
                                                          3,6-anhydro-[d]{.smallcaps}-galactose                                                                    

  GH117 1,3-α-3,6-anhydro-[l]{.smallcaps}-galactosidase                                                                                                            

  Porphyran (Galactan)                                    Sulphated 1,3-β-[d]{.smallcaps}-galactose\    GH16 β-porphyranase\            *Bacteroides plebeius*     \[[@B41-marinedrugs-17-00327],[@B44-marinedrugs-17-00327],[@B45-marinedrugs-17-00327]\]
                                                          1,4-α-[l]{.smallcaps}-galactose-6-sulfate\    GH86 β-porphyranase                                        
                                                          3,6-anhydro-α-[l]{.smallcaps}-galactose                                                                  

  Xylan                                                   1,3-1,4-β-[d]{.smallcaps}-xylose              GH3 xylan 1,4-β-xylosidase      Not determined             \[[@B46-marinedrugs-17-00327],[@B47-marinedrugs-17-00327],[@B48-marinedrugs-17-00327],[@B49-marinedrugs-17-00327]\]

  GH5 endo-1,4-β-xylanase                                                                                                                                          

  GH10 endo-1,4-β-xylanase                                                                                                                                         

  GH10 endo-1,3-β-xylanase                                                                                                                                         

  GH11 endo-β-1,4-xylanase                                                                                                                                         

  GH11 endo-β-1,3-xylanase                                                                                                                                         

  GH43 β-xylosidase                                                                                                                                                

  GH43 xylanase                                                                                                                                                    

  GH43 β-1,3-xylosidase                                                                                                                                            

  GH67 xylan α-1,2-glucuronidase                                                                                                                                   

  GH115 xylan α-1,2-glucuronidase                                                                                                                                  

  CE1−CE7 and CE12 acetyl xylanesterases                                                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PL, Polysaccharide Lyase family; GH, Glycoside Hydrolase family. Potential glycolytic bacteria were identified using the Carbohydrate-Active enZYmes Database \[[@B28-marinedrugs-17-00327]\].

marinedrugs-17-00327-t003_Table 3

###### 

Potential degradation of green seaweed glycans by the human gut microbiota.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Carbohydrate                           Carbohydrate-Active Enzyme (CAZyme)                Evidenced Glycolytic Bacteria         Reference        
  -------------------------------------- -------------------------------------------------- ------------------------------------- ---------------- -------------------------------------------------------------
  Ulvan                                  Sulphated 1,4-β-[d]{.smallcaps}-Glucuronic acid\   GH78 α-[l]{.smallcaps}-rhamnosidase   Not determined   \[[@B50-marinedrugs-17-00327],[@B51-marinedrugs-17-00327]\]
                                         α-[l]{.smallcaps}-Rhamnose\                                                                               
                                         1,4-β-[d]{.smallcaps}-xyloglucan                                                                          

  GH145 α-[l]{.smallcaps}-rhamnosidase                                                                                                             

  Xylan                                  1,3-β-[d]{.smallcaps}-xylose                       GH10 endo-1,3-β-xylanase,             Not determined   \[[@B52-marinedrugs-17-00327]\]

  GH11 endo-β-1,3-xylanase                                                                                                                         

  GH43 β-1,3-xylosidase                                                                                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PL, Polysaccharide Lyase family; GH, Glycoside Hydrolase family. Potential glycolytic bacteria were identified using the Carbohydrate-Active enZYmes Database \[[@B28-marinedrugs-17-00327]\].

marinedrugs-17-00327-t004_Table 4

###### 

In vitro fermentation of brown seaweeds with human faecal inoculum.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Seaweed                  Substrate                                                                              Dose                  Use of a Simulated In Vitro Digestion Before Fermentation?   Experimental Parameters          Microbial Enumeration   Microbial Changes                                                                                                                                                                       Metabolomics Analysis Technique   Metabolite Changes                Reference
  ------------------------ -------------------------------------------------------------------------------------- --------------------- ------------------------------------------------------------ -------------------------------- ----------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- --------------------------------- ----------------------------------
  *Ecklonia radiata*       Crude fraction (CF)\                                                                   1.5% (*w*/*v*)        Yes\                                                         10% (*w*/*v*) pooled inoculum\   qPCR                    `↑`*Bifidobacterium*`↑`*Lactobacillus*\                                                                                                                                                 GC-FID                            `↑`Acetate\                       \[[@B56-marinedrugs-17-00327]\]
                           Phlorotannin-enriched fraction (PF)\                                                                         CF = 71.5% digestible\                                       (n = 3)\                                                 *(LPF)*\                                                                                                                                                                                                                  (CF)\                             
                           Low-molecular weight polysaccharide fraction (LPF)\                                                          PF = 87.3% digestible\                                       24 h                                                     `↑`*F. prausnitzii*`↑`*C. coccoides*\                                                                                                                                                                                     `↑`Propionate\                    
                           High-molecular weight polysaccharide fraction (HPF)                                                          LPF = 86.1% digestible\                                                                                               `↑`*Firmicutes*\                                                                                                                                                                                                          (CF, LPF, HPF)\                   
                                                                                                                                        HPF = non-digestible                                                                                                  (CF, LPF)\                                                                                                                                                                                                                `↑` Butyrate\                     
                                                                                                                                                                                                                                                              `↑`*Bacteroidetes*`↑`*E. coli*\                                                                                                                                                                                           (CF, LPF, HPF)\                   
                                                                                                                                                                                                                                                              (CF, PF, LPF, HPF)\                                                                                                                                                                                                       `↑` Total SCFA\                   
                                                                                                                                                                                                                                                              `↓`*Enterococcus*\                                                                                                                                                                                                        (CF, LPF, HPF)                    
                                                                                                                                                                                                                                                              (CF, PF)                                                                                                                                                                                                                                                    

  *Ecklonia radiata*       Water extract (WE)\                                                                    1.5% (*w*/*v*)        No--digestibility unknown                                    10% (*w*/*v*) pooled inoculum\   qPCR                    = *F. prausnitzii = C. leptum*\                                                                                                                                                         GC-FID                            `↑` Acetate\                      \[[@B57-marinedrugs-17-00327]\]
                           Acid extract (AE)\                                                                                                                                                        (n = 3)\                                                 *= R. bromii* `↑` Total bacteria\                                                                                                                                                                                         `↑` Propionate\                   
                           Celluclast enzyme extract\                                                                                                                                                24 h                                                     (CEE, AEE, WE, FF)\                                                                                                                                                                                                       `↑` Butyrate\                     
                           (CEE)\                                                                                                                                                                                                                             `↑` *Bifidobacterium* `↑` *Bacteroidetes*\                                                                                                                                                                                (WE, AE, CEE, AEE, FF, PF, SP)\   
                           Alcalase enzyme extract (AEE)\                                                                                                                                                                                                     `↑` *Lactobacillus* `↑` *C. coccoides*\                                                                                                                                                                                   `↑` Total SCFA                    
                           Free sugar fraction (FF)\                                                                                                                                                                                                          (CEE)\                                                                                                                                                                                                                                                      
                           Polysaccharide fraction (PF)\                                                                                                                                                                                                      `↑` *E. coli* `↑` *Enterocccus*\                                                                                                                                                                                                                            
                           Seaweed residue (SR)\                                                                                                                                                                                                              (WE, AE, CEE, AEE, FF, PF, SP)                                                                                                                                                                                                                              
                           Seaweed powder (SP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *Sargassum muticum*      *Sargassum muticum* Alcalase enzyme extract (SAE)                                      1% (*w*/*v*)          Yes--non-digestible (% digestible undisclosed)               10% (*w*/*v*) single inoculum\   FISH                    = *Bifidobacterium*\                                                                                                                                                                    HPLC                              `↑` Total SCFA                    \[[@B99-marinedrugs-17-00327]\]
                                                                                                                                                                                                     24 h                                                     *= Lactobacillus*\                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                              *= Clostridium histolticum*\                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                              `↑` *Bacteroides/Prevotella*\                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                              `↓` *C.coccoides/E.rectale*                                                                                                                                                                                                                                 

  *Sargassum thunbergii*   Polysaccharide extract                                                                 0.3% (*w*/*v*)        No--digestibility unknown                                    20% (*w*/*v*) pooled inoculum\   16S rRNA\               `↑` Bacteroidetes\                                                                                                                                                                      GC-MS                             `↑` Acetate\                      \[[@B55-marinedrugs-17-00327]\]
                                                                                                                                                                                                     (n = 3)\                         NGS                     `↑`Bacteroidetes:Firmicutes ratio\                                                                                                                                                                                        `↑` Propionate\                   
                                                                                                                                                                                                     24 h                                                     `↑` *Bifidobacterium*\                                                                                                                                                                                                    `↑` Butyrate\                     
                                                                                                                                                                                                                                                              `↑` *Roseburia*\                                                                                                                                                                                                          `↑` Valerate\                     
                                                                                                                                                                                                                                                              `↑` *Parasutterella*\                                                                                                                                                                                                     `↑` Total SCFA                    
                                                                                                                                                                                                                                                              `↑` *Fusicatenibacter*\                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                              `↑` *Coprococcus*\                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                              `↑` *Fecalibacterium*                                                                                                                                                                                                                                       

  *-*                      Alginate                                                                               5% (*w*/*v*)          No--digestibility unknown                                    10% (*w*/*v*) single inoculum\   16S rRNA\               `↑` *Bacteroides*                                                                                                                                                                       GC-FID                            `↑` Propionate\                   \[[@B33-marinedrugs-17-00327]\]
                                                                                                                                                                                                     72 h                             DGGE\                                                                                                                                                                                                                                             `↑` Butyrate\                     
                                                                                                                                                                                                                                      16S rRNA\                                                                                                                                                                                                                                         `↑` Total SCFA                    
                                                                                                                                                                                                                                      NGS                                                                                                                                                                                                                                                                                 

  \-                       Alginate (A)\                                                                          5 g/L (A)\            No--digestibility unknown                                    10% (*w*/*v*) single inoculum\   16S rRNA DGGE           Detection of *Bacteroides xylanisolvens, Clostridium clostridioforme/Clostridium symbiosum, Bacteroides finegoldii, Shigella flexneri/E.coli, E.fergusonii,* and *Bacteroides ovatus*   HPLC                              A, MO, GO:\                       \[[@B36-marinedrugs-17-00327]\]
                           Mannuronic acid oligosaccharides (MO)\                                                 8 g/L (MO, GO, PSS)                                                                48 h                                                                                                                                                                                                                                                                               `↑` Acetate\                      
                           Guluronic acid oligosaccharides (GO) Propylene glycol alginate sodium sulphate (PSS)                                                                                                                                                                                                                                                                                                                                                                         `↑` Propionate\                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        `↑` Butyrate\                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        `↑` Total SCFA                    

  *Ascophyllum nodosum*    Sulphated polysaccharide extract                                                       9 mg/mL               Yes--non-digestible (% digestible undisclosed)               10% (*w*/*v*)\                   16S rRNA NGS            `↑` *Bacteroides*\                                                                                                                                                                      GC-FID                            `↑` Acetate\                      \[[@B100-marinedrugs-17-00327]\]
                                                                                                                                                                                                     pooled inoculum\                                         `↑` *Phascolarctobacterium*\                                                                                                                                                                                              `↑` Propionate\                   
                                                                                                                                                                                                     (n = 4)\                                                 `↑` *Oscillospira*\                                                                                                                                                                                                       `↑` Butyrate\                     
                                                                                                                                                                                                     24 h                                                     `↑` *Fecalibacterium*                                                                                                                                                                                                     `↑` Total SCFA                    

  *Laminaria digitata*     Crude polysaccharide extract (CE)\                                                     1% (*w*/*v*)          Yes--non-digestible (% digestible undisclosed)               20% (*w*/*v*) pooled inoculum\   16S rRNA NGS            `↑`*Parabacteroides* (CE, DE)\                                                                                                                                                          GC-FID                            `↑` Acetate (CE, DE)\             \[[@B101-marinedrugs-17-00327]\]
                           Depolymerised crude polysaccharide extract (DE)                                                                                                                           (n = 3)\                                                 `↑` *Fibrobacter* (CE)\                                                                                                                                                                                                   `↑` Propionate (CE, DE)\          
                                                                                                                                                                                                     48 h                                                     `↓` *Streptococcus*\                                                                                                                                                                                                      `↑` Butyrate (CE, DE)\            
                                                                                                                                                                                                                                                              `↓` *Ruminococcus*\                                                                                                                                                                                                       `↑` Total SCFA (CE, DE)           
                                                                                                                                                                                                                                                              `↑` *Lachnospiraceae* UC (DE)\                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                              `↓` *Peptostreptococcaceae* IS (DE)\                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                              `↑` *Dialister* (CE, DE)\                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                              `↑` γ B38UC (CE)                                                                                                                                                                                                                                            

  \-                       Laminarin                                                                              1% (*w*/*v*)          No--digestibility unknown                                    10% (*w*/*v*) pooled inoculum\   qPCR                    `↑` *Bifidobacterium*\                                                                                                                                                                  HPLC                              `↑` Acetate\                      \[[@B79-marinedrugs-17-00327]\]
                                                                                                                                                                                                     (n = 5)\                                                 `↑` *Bacteroides*                                                                                                                                                                                                         `↑` Propionate\                   
                                                                                                                                                                                                     24 h                                                                                                                                                                                                                                                                               `↑` Total SCFA                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector; FISH, Flourescence in situ Hybridisation; 16S rRNA NGS, 16S rRNA Next Generation Sequencing; HPLC, High Performance Liquid Chromaography; GC-MS, Gas Chromatography-Mass Spectrometry; 16S rRNA DGGE, 16S rRNA Denaturing Gradient Gel Electrophoresis; 16S rRNA NGS, 16S rRNA Next Generation Sequencing; GC-FID, Gas Chromatography with Flame Ionisation Detector; HPLC, High Performance Liquid Chromaography; 16S rRNA NGS, 16S rRNA Next Generation Sequencing; qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector; HPLC, High Performance Liquid Chromatography; SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; `↑`, significant increase compared to the control; `↓` significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.

marinedrugs-17-00327-t005_Table 5

###### 

In vitro fermentation of red seaweeds with human faecal inoculum.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Seaweed                   Substrate                     Dose           Use of a Simulated in vitro Digestion Before Fermentation?   Experimental Parameters                  Microbial Enumeration   Microbial Changes               Metabolomics Analysis Technique   Metabolite Changes   Reference
  ------------------------- ----------------------------- -------------- ------------------------------------------------------------ ---------------------------------------- ----------------------- ------------------------------- --------------------------------- -------------------- ----------------------------------
  *Kappaphycus alvarezii*   Whole Seaweed (WS)            1% (*w*/*v*)   Yes--non-digestible\                                         10% (*w*/*v*) single inoculum\           FISH                    `↑` *Bifidobacterium*\          HPLC                              `↑` Total SCFA       \[[@B13-marinedrugs-17-00327]\]
                                                                         (% digestible undisclosed)                                   24 h                                                             `↓` *Clostridium coccoides/*\                                                          
                                                                                                                                                                                                       *Eubacterium rectale*                                                                  

  *Osmundea pinnatifida*    *Osmundea pinnatifida*\       1% (*w*/*v*)   Yes--non-digestible\                                         10% (*w*/*v*) single inoculum\           FISH                    = *Bifidobacterium*\            HPLC                              `↑`Total SCFA        \[[@B99-marinedrugs-17-00327]\]
                            Viscozyme extract (OVE)                      (% digestible undisclosed)                                   24 h                                                             *= Lactobacillus*\                                                                     
                                                                                                                                                                                                       *= Clostridium histolticum*                                                            

  *Gracilaria rubra*        Polysaccharide extract (PE)   1%\            Yes--non-digestible\                                         10% (*w*/*v*) pooled\                    16S rRNA\               `↑`*Bacteroides*\               GC-FID                            `↑` Acetate\         \[[@B117-marinedrugs-17-00327]\]
                                                          (*w*/*v*)      (% digestible undisclosed)                                   inoculum (n = 4)\                        NGS                     `↑`*Prevotella*\                                                  `↑` Propionate\      
                                                                                                                                      24 h                                                             `↑`*Phascolarctobacterium*\                                       `↑` Isobutyrate\     
                                                                                                                                                                                                       `↓`Firmicutes:Bacteroidetes                                       `↑` Total SCFA       

  \-                        Porphyran                     1% (*w*/*v*)   No--digestibility unknown                                    10% (*w*/*v*) pooled inoculum (n = 5)\   qPCR                    `↑` *Bifidobacterium*\          HPLC                              = Acetate\           \[[@B79-marinedrugs-17-00327]\]
                                                                                                                                      24 h                                                             `↑` *Bacteroides*                                                 = Propionate\        
                                                                                                                                                                                                                                                                         = Butyrate\          
                                                                                                                                                                                                                                                                         = Total SCFA         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FISH, Flourescence in situ Hybridisation; 16S rRNA NGS, 16S rRNA Next Generation Sequencing; qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector; HPLC, High Performance Liquid Chromatography; SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; `↑`, significant increase compared to the control; `↓` significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.

marinedrugs-17-00327-t006_Table 6

###### 

In vitro fermentation of green seaweeds with human faecal inoculum.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Seaweed                    Substrate                     Dose               Use of a Simulated in vitro Digestion Before Fermentation?   Experimental Parameters                    Microbial Enumeration   Microbial Changes                                         Metabolomics Analysis Technique   Metabolite Changes   Reference
  -------------------------- ----------------------------- ------------------ ------------------------------------------------------------ ------------------------------------------ ----------------------- --------------------------------------------------------- --------------------------------- -------------------- ---------------------------------
  *Enteromorpha prolifera*   Polysaccharide extract (PE)   0.2 g in 9.5 mL\   Yes-non-digestible\                                          10.5% (*w*/*v*) pooled inoculum (n = 3)\   Microbial culture       `↑`*Enterobacter* (0.2 PE and 0.8 PE at 24 h and 48 h)\   GC-FID                            = Acetate\           \[[@B12-marinedrugs-17-00327]\]
                                                           0.8 g in 9.5mL     (% digestible undisclosed)                                   12, 24, and 48 h                                                   = *Enterococcus*\                                                                           = Butyrate\          
                                                                                                                                                                                                              *= Lactobacillus*\                                                                          = Lactate            
                                                                                                                                                                                                              *= Bifidobacterium*                                                                                              

  \-                         Ulvan                         1% (*w*/*v*)       No-digestibility unknown                                     10% (*w*/*v*) pooled inoculum (n = 5)\     qPCR                    `↑` *Bifidobacterium*\                                    HPLC                              `↑` Acetate\         \[[@B79-marinedrugs-17-00327]\]
                                                                                                                                           24 h                                                               `↑` *Lactobacillus*                                                                         `↑` Lactate          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector; HPLC, High Performance Liquid Chromatography; =, no statistical difference compared to the control; `↑`, significant increase compared to the control; `↓` significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.

marinedrugs-17-00327-t007_Table 7

###### 

Impact of seaweeds on the rodent gut microbiota.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Animal                        Substrate                                                   Dose                               Duration   Biological Sample   Microbial Changes                                                                                                            Metabolite Changes                             Reference
  ----------------------------- ----------------------------------------------------------- ---------------------------------- ---------- ------------------- ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------
  30 Male Sprague-Dawley Rats   *Chondrus crispus*\                                         0.5% (*w*/*w*)\                    21 days    Faeces              `↑`*Bifidobacterium*`↑`*Legionella*`↑`*Sutterella*\                                                                          `↑` Acetate\                                   \[[@B15-marinedrugs-17-00327]\]
                                Whole Seaweed (WS)                                          2.5% (*w*/*w*)                                                    `↑`*Blautia*`↑`*Holdemania*\                                                                                                 `↑` Propionate (2.5% WS)\                      
                                                                                                                                                              `↑`*Shewanella*`↑`*Agarivorans*\                                                                                             `↑` Butyrate\                                  
                                                                                                                                                              `↓`*Streptococcus*\                                                                                                          `↑` Total SCFA                                 
                                                                                                                                                              `↑`*Bifidobacterium breve* (2.5% WS)                                                                                                                                        

  24 Male Sprague-Dawley Rats   *Ecklonia radiata* Whole Seaweed (WS)\                      5% (*w*/*w*) WS\                   7 days     Caecum              `↑`*F. prausnitzii*`↑`*E. coli* (PF)\                                                                                        `↑` Acetate\                                   \[[@B129-marinedrugs-17-00327]\]
                                Ecklonia radiata Polysaccharide Fraction (PF)               5% (*w*/*w*) PF                                                   `↓` *Enterococcus* (WS)\                                                                                                     `↑` Propionate\                                
                                                                                                                                                              `↓`*Lactobacillus* `↓`*Bifidobacterium*\                                                                                     `↑` Butyrate (PF)\                             
                                                                                                                                                              `↓` Firmicutes:Bacteroidetes                                                                                                 `↓` Valerate\                                  
                                                                                                                                                                                                                                                                                           `↓` Hexanoate\                                 
                                                                                                                                                                                                                                                                                           `↑` Total SCFA\                                
                                                                                                                                                                                                                                                                                           `↓` i-Butyrate\                                
                                                                                                                                                                                                                                                                                           `↓` i-Valerate\                                
                                                                                                                                                                                                                                                                                           `↓` phenol\                                    
                                                                                                                                                                                                                                                                                           `↓` p-cresol                                   

  18 Male Wistar Rats           Alginate (A)\                                               2% (*w*/*w*)                       14 days    Caecum              `↑`*Bacteroides* (*Bacteroides capillosus*)\                                                                                 `↑` Propionate (L)\                            \[[@B97-marinedrugs-17-00327]\]
                                Laminarin (L)\                                                                                                                Presence of *Enterorhabdus* (A)\                                                                                             `↑` Total SCFA (A, L)                          
                                Fucoidan (F)                                                                                                                  `↑` Proteobacteria. Presence of *Lachnospiracea, Parabacteroides* (*Parabacteroides distasonis*) and *Parasutterella* (L)\                                                  
                                                                                                                                                              Not fermented (F)                                                                                                                                                           

  16 Male\                      *Saccorhiza polyschides* extract (BAE)                      High fat diet + 5% (*w*/*w*) BAE   8 months   Faeces              `↓` Faecal bile salt hydrolase activity                                                                                      `↓` Secondary bile acids                       \[[@B54-marinedrugs-17-00327]\]
  C57 BL/6 Mice                                                                                                                                                                                                                                                                                                                           

  18 Male Wistar Rats           Alginate (A)\                                               2% (*w*/*w*)                       14 days    Caecum              `↑`*Lactobacillus*`↑`*Porphyromonas*`↑`*Coprobacillus*\                                                                      `↑` Lactic acid (L)\                           \[[@B130-marinedrugs-17-00327]\]
                                Laminarin (L)                                                                                                                 `↑`*Oscillibacter valencigenes*\                                                                                             = Acetate\                                     
                                                                                                                                                              `↓`*Parabacteroides* (L)\                                                                                                    = Propionate\                                  
                                                                                                                                                              `↑` *Catabacter honkongensis*\                                                                                               = Butyrate\                                    
                                                                                                                                                              `↑` *Stomatobaculum longum*\                                                                                                 = Total SCFA\                                  
                                                                                                                                                              `↓` *Adlercreuzia* (A)\                                                                                                      `↓` Indole                                     
                                                                                                                                                              `↓` *Helicobacter* (A, L)                                                                                                                                                   

  18 Male C57BL/6 mice          *Ascophyllum nodosum* Fucoidan (FuA)\                       100 mg/kg/day                      6 weeks    Caecum              `↑`*Lactobacillus*`↑`*Anaeroplasma*\                                                                                         \-                                             \[[@B96-marinedrugs-17-00327]\]
                                *Laminaria*\                                                                                                                  `↑`*Thalassospira* (FuA)\                                                                                                                                                   
                                *japonica* Fucoidan (FuL)                                                                                                     `↑`*Ruminococcaceae* `↓` *Alistipes*\                                                                                                                                       
                                                                                                                                                              `↓` Clostridiales\                                                                                                                                                          
                                                                                                                                                              `↓` *Akkermansia* (FuL)\                                                                                                                                                    
                                                                                                                                                              `↓` *Candidatus `↓`* *Arthromitus*\                                                                                                                                         
                                                                                                                                                              `↓` *Peptococcus*\                                                                                                                                                          
                                                                                                                                                              `↓` *Lachnospiraceae Incertae Sedis* (FuA, FuL)                                                                                                                             

  15 Male Wistar rats           *Ascophyllum nodosum* seaweed crude polysaccharide (SCP)\   0.2 g per 180 --200 g rat weight   4 days     Faeces              \-                                                                                                                           `↑` Acetate (HA \> A \> SCPH Lp \> SCPH Ef)\   \[[@B131-marinedrugs-17-00327]\]
                                SCP *Lactobacillus plantarum* hydrolysate (SCPH Lp)\                                                                                                                                                                                                       `↑` Propionate (HA = A = SCPH Lp = SCPH Ef)\   
                                SCP *Enterococcus fecalis* hydrolysate (SCPH Ef)\                                                                                                                                                                                                          `↑` Butyrate (HA = A = SCPH Lp = SCPH Ef)\     
                                Alginate (A)\                                                                                                                                                                                                                                              (relative to day zero)                         
                                Hydrolysed Alginate (HA)                                                                                                                                                                                                                                                                                  

  32 Female Kunming mice        *Enteromorpha prolifera* (EP)\                              1:5 (*w*/*w*)                      7 days     Faeces              `↑`Alpha diversity (EP)\                                                                                                     \-                                             \[[@B119-marinedrugs-17-00327]\]
                                *Enteromorpha* polysaccharide extract (PEP)                                                                                   `↑`*Bacteroidales S24-7* (EP)\                                                                                                                                              
                                                                                                                                                              `↑` *Prevotellaceae* (PEP)\                                                                                                                                                 
                                                                                                                                                              `↑` Firmicutes `↑`Actinobacteria (EP, PEP)\                                                                                                                                 
                                                                                                                                                              `↓` Bacteroidetes `↓` Proteobacteria (EP, PEP)                                                                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; `↑`, significant increase compared to the control; `↓` significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.

marinedrugs-17-00327-t008_Table 8

###### 

Impact of seaweeds on the porcine gut microbiota.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Animal                             Seaweed Component                     Dose                           Duration                                 Biological Sample             Microbial Changes                               Metabolite Changes   Reference
  ---------------------------------- ------------------------------------- ------------------------------ ---------------------------------------- ----------------------------- ----------------------------------------------- -------------------- ----------------------------------
  20 pregnant gilts and 48 piglets   Laminarin/Fucoidan Extract            10 g/day                       Gestation (day 83) to weaning (day 28)   Faeces (Sow)\                 Sows (parturition): `↓` *Enterobacteriaceae*\   \-                   \[[@B207-marinedrugs-17-00327]\]
                                                                                                                                                   Colonic digesta (Piglet)      *= Lactobacilli*\                                                    
                                                                                                                                                                                 Piglets (birth, 48h after birth, weaning):\                          
                                                                                                                                                                                 = *Enterobacteriaceae = Lactobacilli*                                

  200 pigs                           *Ecklonia cava* Whole Seaweed         0.05% (*w*/*w*)\               28 days                                  Caecum                        `↑`*Lactobacillus*\                             \-                   \[[@B208-marinedrugs-17-00327]\]
                                                                           0.1% (*w*/*w*)\                                                                                       `↓`*E. coli*\                                                        
                                                                           0.15% (*w*/*w*)                                                                                       = Total Anaerobes                                                    

  24 pigs                            Laminarin/Fucoidan\                   5.37 Kg/tonne SD\              21 days                                  Ileum\                        *= Bifidobacteria*\                             \-                   \[[@B209-marinedrugs-17-00327]\]
                                     Extract (SD)\                         26.3 Kg/tonne WS                                                        Caecum\                       *= Lactobacillus*\                                                   
                                     Laminarin/Fucoidan Wet Seaweed (WS)                                                                           Colon                         *= Enterobacterium* (SD, WS)\                                        
                                                                                                                                                                                 `↑`*Lactobacillus agilis* (colon)                                    

  48 pigs                            Laminarin Extract                     300 ppm                        32 days                                  Faeces                        `↑` *Lactobacillus*\                            = Acetate\           \[[@B210-marinedrugs-17-00327]\]
                                                                                                                                                                                 *= Bifidobacteria*                              `↓` Propionate\      
                                                                                                                                                                                                                                 = Butyrate\          
                                                                                                                                                                                                                                 = Valerate\          
                                                                                                                                                                                                                                 = i-Butyrate\        
                                                                                                                                                                                                                                 = i-Valerate         

  48 pigs                            β-glucan                              250 g/tonne\                   29 days                                  Ileum\                        = *Lactobacilli*\                               \-                   \[[@B211-marinedrugs-17-00327]\]
                                                                           150 g/tonne                                                             Caecum\                       = *Bifidobacteria.*\                                                 
                                                                                                                                                   Proximal Colon Distal Colon   `↑` *Lactobacillus* diversity                                        

  168 pigs                           Laminarin (L)\                        240 mg/kg F\                   35 days                                  Faeces                        = *E. coli*\                                    = Acetate\           \[[@B212-marinedrugs-17-00327]\]
                                     Fucoidan (F)                          150 mg/kg L\                                                                                          = *Bifidobacteria*\                             = Propionate\        
                                                                           300 mg/kg L\                                                                                          `↑` *Lactobacilli*                              = Butyrate\          
                                                                           150 mg/kg L and 240 mg/kg F\                                                                                                                          = Valerate\          
                                                                           300 mg/kg L and 240 mg/kg F                                                                                                                           = i-Butyrate\        
                                                                                                                                                                                                                                 = i-Valerate\        
                                                                                                                                                                                                                                 = Total SCFA         

  9 pigs                             Alginate                              5.14% (*w*/*w*)                84 days                                  Faeces                        = Diversity\                                    \-                   \[[@B199-marinedrugs-17-00327]\]
                                                                                                                                                                                 `↑` Unclassified F16 family\                                         
                                                                                                                                                                                 `↓` *Clostridiaceae*\                                                
                                                                                                                                                                                 `↓` Unclassified RF39 (Mollicutes)\                                  
                                                                                                                                                                                 `↑` *Ruminococcus*\                                                  
                                                                                                                                                                                 `↑` *Roseburia*\                                                     
                                                                                                                                                                                 `↑` unclassified *F16* genus (TM7)\                                  
                                                                                                                                                                                 `↑` *Lachnospira*\                                                   
                                                                                                                                                                                 `↓` *Blautia*                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

=, no statistical difference compared to the control; `↑`, significant increase compared to the control; `↓` significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.

marinedrugs-17-00327-t009_Table 9

###### 

Impact of seaweeds on the hen gut microbiota.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Animal            Seaweed Component               Dose                                   Duration   Biological Sample   Microbial Changes                                      Metabolite Changes        Reference
  ----------------- ------------------------------- -------------------------------------- ---------- ------------------- ------------------------------------------------------ ------------------------- ----------------------------------
  160 laying hens   *Chondrus crispus*\             0.5% (*w*/*w*)\                        30 days    Ileum\              `↑`*Bifidobacterium longum* (CC2, SG1, SG2)\           `↑` Acetate (CC1, SG1)\   \[[@B200-marinedrugs-17-00327]\]
                    Whole Seaweed (CC)\             1% (*w*/*w*)\                                     Caecal digesta      `↑`*Streptococcus salivarius* (CC1, CC2, SG2)\         `↑` Propionate (CC2)\     
                    *Sarcodiotheca gaudichaudii*\   2% (*w*/*w*)                                                          `↓`*Clostridium perfringen*s (CC1, CC2, SG1, SG2)\     `↑` Butyrate (SC2)        
                    Whole Seaweed (SG)                                                                                    `↓`*Lactobacillus acidophilus* (CC1, CC2)                                        

  96 laying hens    *Chondrus crispus*\             Control diet + 2% (*w*/*w*) seaweed\   28 days    Caecum              `↑`*Lactobacillus acidophilus* (CC4)\                  `↑` Propionate (CC4)      \[[@B201-marinedrugs-17-00327]\]
                    Whole Seaweed (CC)\             Control diet + 4% (*w*/*w*) seaweed                                   `↓`*Bifidobacterium longum* (SG2, SG4, CC4)\                                     
                    *Sarcodiotheca gaudichaudii*\                                                                         `↓` *Streptococcus salivarius* (SG2, SG4, CC2, CC4)\                             
                    Whole Seaweed (SG)                                                                                    `↑` Bacteroidetes (SG4, CC2, CC4)                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

=, no statistical difference compared to the control; `↑`, significant increase compared to the control; `↓` significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.
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###### 

In vitro fermentation of seaweeds with cow rumen inoculum.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Seaweed                           Substrate       Experimental Parameters    Dose (*w*/*v*)   Microbial Enumeration   Microbial Changes   Metabolomics Analysis Technique   Metabolite Changes                 Reference
  --------------------------------- --------------- -------------------------- ---------------- ----------------------- ------------------- --------------------------------- ---------------------------------- ----------------------------------
  *Ascophyllum nodosum* (AN)\       Whole Seaweed   50% pooled inoculum\       0.5 g/L\         \-                      \-                  GC-FID                            `↑`Propionate\                     \[[@B213-marinedrugs-17-00327]\]
  *Laminaria digitata* (LD)                         (n = 4)\                   1 g/L\                                                                                         `↑`Butyrate (LD)\                  
                                                    24 h                       2 g/L                                                                                          `↓` BCFA\                          
                                                                                                                                                                              `↓`Methane                         

  *Asparagopsis taxiformis*         Whole Seaweed   20% pooled inoculum\       0.5%\            \-                      \-                  GC-FID                            `↓` Total gas production\          \[[@B214-marinedrugs-17-00327]\]
                                                    (n = 4)\                   1%\                                                                                            `↓` Methane\                       
                                                    72 h                       2%\                                                                                            `↓` Acetate\                       
                                                                               5%\                                                                                            `↑` Propionate\                    
                                                                               10%                                                                                            `↑` Butyrate (2%, 10%)\            
                                                                                                                                                                              `↓` Total SCFA (5%, 10%)           

  *Ulva sp.*\                       Whole Seaweed   20% pooled inoculum\       25%              \-                      \-                  GC-FID                            `↓` Methane                        \[[@B215-marinedrugs-17-00327]\]
  *Laminaria ochroleuca*\                           (n = 2)\                                                                                                                                                     
  *Saccharina latissima*\                           24 h                                                                                                                                                         
  *Gigartina sp.*\                                                                                                                                                                                               
  *Gracilaria vermiculophylla*                                                                                                                                                                                   

  Brown seaweed by-products (BSB)   \-              50% (*v*/*v*)\             2%\              \-                      \-                  GC-FID                            `↓` Ammonia (3, 9, 12 and 24 h)\   \[[@B216-marinedrugs-17-00327]\]
                                                    single inoculum\           4%                                                                                             `↓` Total SCFA (24 h)              
                                                    0, 3, 6, 9, 12, and 24 h                                                                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GC-FID, Gas Chromatography; =, no statistical difference compared to the control; `↑`, significant increase compared to the control; `↓` significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.
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###### 

Impact of seaweeds on the sheep rumen microbiota.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Seaweed                      Dose   Experimental Parameters                                    Microbial Enumeration   Microbial Changes                                  Metabolomics Analysis Technique   Metabolite Changes                  Reference
  ---------------------------- ------ ---------------------------------------------------------- ----------------------- -------------------------------------------------- --------------------------------- ----------------------------------- ----------------------------------
  *Asparagopsis taxiformis*\   2%     in vitro batch culture fermentation\                       16S rRNA NGS\           `↓`Methanogens\                                    GC-MS                             `↓` Total Gas\                      \[[@B203-marinedrugs-17-00327]\]
  Whole Seaweed                       20% (*v*/*v*) pooled sheep rumen fluid inoculum (n = 4)\   qPCR                    `↓`Bacteroidetes/Firmicutes ratio\                                                   `↓` Methane\                        
                                      48 and 72 h                                                                        `↓` mcrA gene expression                                                             `↑` Hydrogen                        

  *Ascophyllum nodosum*\       1%\    Rams (n = 8)\                                              16S rRNA NGS            `↓` undefined *TM7-1*\                             GC-FID                            Dose dependent:\                    \[[@B204-marinedrugs-17-00327]\]
  Whole Seaweed                3%\    21 days *ad libitum*                                                               `↓`undefined *Coriobacteriaceae* `↓`*Roseburia*\                                     ↑ Acetate\                          
                               5%                                                                                        `↓`*Coprococcus*\                                                                    ↓ Propionate\                       
                                                                                                                         `↓`*Prevotella copri*\                                                               ↓ Butyrate\                         
                                                                                                                         `↑`*Blautia producta*\                                                               PICRUSt:\                           
                                                                                                                         `↑` *Entodinium species 1*\                                                          `↑`Butanoate metabolism\            
                                                                                                                         `↑`*Veillonellaceae*                                                                 `↑` Fatty acid metabolism\          
                                                                                                                                                                                                              `↓`Glycerophospholipid metabolism   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

16S rRNA NGS, 16S rRNA Next Generation Sequencing; qPCR, Quantitative PCR; GC-FID, Gas Chromatography; =, no statistical difference compared to the control; `↑`, significant increase compared to the control; `↓` significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.
